Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk-2636771. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB known ✓ | P42338 | 5/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 16/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-2636771 SCHEMBL29411881 | 1.00 | PIK3C2B (1.00) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| Gsk-2636771 SCHEMBL1280998 | 1.00 | PIK3C2B (1.00) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| Gsk-2636771 SCHEMBL16323314 | 0.99 | PIK3C2B (0.98) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| Gsk-2636771 SCHEMBL1281470 | 0.94 | PIK3C2B (0.89) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL26003142 | 0.94 | PIK3C2B (0.89) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1280975 | 0.93 | PIK3C2B (0.87) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL1633027 | 0.93 | PIK3C2B (0.87) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL1281683 | 0.92 | PIK3C2B (0.86) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL1281893 | 0.92 | PIK3C2B (1.00) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL1282107 | 0.92 | PIK3C2B (0.87) | PIK3C2BPIK3CBPIK3CDPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1742 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4709384-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4709382-A1 | METHODS OF TREATING SQUAMOUS CELL CARCINOMA WITH A FARNESYLTRANSFERASE INHIBITOR AND A PI3K INHIBITOR | Kura Oncology, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| WO-2025264581-A1 | P110 INHIBITORS FOR THE TREATMENT OF CANCER | LEAPFROG BIO, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | claimed |
| WO-2025217056-A2 | VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) RECEPTOR ANTAGONISTS FC FUSIONS AND METHODS OF USE | CAMBIUM ONCOLOGY (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4629995-A1 | COMBINATION THERAPY FOR THE TREATMENT OF GLYOBLASTOMA | The University of Florida Research Foundation, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-109311876-B | Heteroaryl estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2022-05-03 | — | — | CN | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| WO-2022076517-A1 | SUBJECT-SPECIFIC TREATMENTS FOR VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-04-14 | — | — | WO | claimed |
| US-20220096640-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-03-31 | — | — | US | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| EP-3972695-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | claimed |
| WO-2022047008-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| US-11246907-B2 | Immunosuppressive agents and their use in therapy | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2022-02-15 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | PIK3CB 276/4885PIK3C2B 106/4885PIK3CD 202/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | PIK3CB 99/4885PIK3C2B 161/4885PIK3CD 18/4885 |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | WEE1, ERBB3, ERBB2 | PIK3CB 230/4885PIK3C2B 250/4885PIK3CD 206/4885 |
| US-20220096640-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | PIK3CB 3344/4885PIK3C2B 4117/4885PIK3CD 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.